Stay updated with breaking news from 75991610. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Repligen Co. (NASDAQ:RGEN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the nine brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month price target […]
Repligen Co. (NASDAQ:RGEN – Free Report) – Stock analysts at William Blair cut their Q1 2024 earnings per share (EPS) estimates for shares of Repligen in a research report issued to clients and investors on Thursday, February 22nd. William Blair analyst M. Larew now forecasts that the biotechnology company will earn $0.30 per share for […]
Primecap Management Co. CA boosted its position in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 6.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,629 shares of the biotechnology company’s stock after purchasing an additional 3,250 shares […]
Repligen Co. (NASDAQ:RGEN – Get Free Report) gapped down prior to trading on Wednesday . The stock had previously closed at $199.73, but opened at $187.80. Repligen shares last traded at $198.30, with a volume of 185,706 shares changing hands. Wall Street Analysts Forecast Growth A number of brokerages recently weighed in on RGEN. KeyCorp […]
DekaBank Deutsche Girozentrale grew its stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 1.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,457 shares of the biotechnology company’s stock after buying an additional 159 shares […]